How to minimize toxic exposure to pyridine during continuous infusion of ceftazidime in patients with cystic fibrosis?

Bourget, P; Amin, A; Dupont, C; Abely, M; Desmazes-Dufeu, N; Dubus, J C; Jouani, B-L; Merlette, C; Nové-Josserand, R; Pages, J; Panzo, R; Vidal, F; Voge, F; Hubert, D

Bourget, P; Amin, A; Dupont, C; Abely, M; Desmazes-Dufeu, N; Dubus, J C; Jouani, B-L; Merlette, C; Nové-Josserand, R; Pages, J; Panzo, R; Vidal, F; Voge, F; Hubert, D.

Affiliation

Bourget P; University Hospital Necker-Enfants Malades, Clinical Pharmacy Department, Paris, France.

Antimicrob Agents Chemother ; 58(5): 2849-55, 2014 May.

Article in En | MEDLINE | ID: mdl-24614367

Subject(s)

Anti-Bacterial Agents/administration & dosage; Anti-Bacterial Agents/chemistry; Ceftazidime/administration & dosage; Cystic Fibrosis/metabolism; Pyridines/toxicity; Ceftazidime/chemistry; Humans; Infusions, Intravenous; Kinetics; Pyridines/chemistry

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Ceftazidime / Cystic Fibrosis / Anti-Bacterial Agents Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2014 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google